Sugi Predict

Sugi Predict / Compounds / SCHEMBL5537348

SCHEMBL5537348

SCHEMBL5537348

COC(=O)Cc1ccc(-c2c(C)cc(OS(=O)(=O)C(F)(F)F)cc2C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 1/20 0.43
▸ CYP4A11 Q02928 1/20 0.43
▸ LMNA P02545 2/20 0.42
▸ SMN1; SMN2 Q16637 5/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ RXRA P19793 1/20 0.39
▸ RXRB P28702 1/20 0.39
▸ RXRG P48443 1/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ PDK2 Q15119 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ PPARG P37231 1/20 0.38
▸ PPARA Q07869 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538841 0.88 CYP4F2 (0.43) CYP4F2CYP4A11LMNASMN1; SMN2NPC1
SCHEMBL6296930 0.83 CYP4F2 (0.54) CYP4F2CYP4A11LMNASMN1; SMN2NPC1
SCHEMBL5536191 0.82 RXRA (0.43) CYP4F2CYP4A11SMN1; SMN2NPC1RAB9A
SCHEMBL491756 0.80 HSP90AB1 (0.49) CYP4F2CYP4A11LMNASMN1; SMN2MEN1
SCHEMBL5538816 0.80 LMNA (0.47) CYP4F2CYP4A11LMNASMN1; SMN2NPC1
SCHEMBL5538854 0.79 CYP4F2 (0.45) CYP4F2CYP4A11LMNASMN1; SMN2RXRA
SCHEMBL2127345 0.79 CYP4F2 (0.43) CYP4F2CYP4A11LMNASMN1; SMN2NPC1
SCHEMBL13745300 0.78 HSP90AB1 (0.44) CYP4F2CYP4A11LMNASMN1; SMN2NPC1
SCHEMBL5536144 0.78 ALDH1A1 (0.45) CYP4F2CYP4A11LMNASMN1; SMN2NPC1
SCHEMBL23668256 0.77 PTGDR (0.46) LMNASMN1; SMN2NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108602-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2012-05-03 — — US disclosed
US-20120108602-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2012-05-03 — — US disclosed
US-7994179-B2 Carbamoyl compounds as DGAT1 inhibitors 190 ASTRAZENECA AB (SE) 2011-08-09 — — US disclosed
US-7994179-B2 Carbamoyl compounds as DGAT1 inhibitors 190 ASTRAZENECA AB (SE) 2011-08-09 — — US disclosed
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2009-12-03 — — US disclosed
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2009-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108602-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 DGAT1, DGAT2, SOAT1 CYP4F2 543/4885CYP4A11 1335/4885LMNA 2705/4885
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 DGAT1, DGAT2, SOAT1 CYP4F2 548/4885CYP4A11 1373/4885LMNA 2683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.